85 related articles for article (PubMed ID: 6726433)
21. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
22. 131-I-meta-iodobenzylguanidine in treatment of malignant phaeochromocytomas.
Vetter H; Fischer M; Müller-Rensing R; Vetter W; Winterberg B
Lancet; 1983 Jul; 2(8341):107. PubMed ID: 6134943
[No Abstract] [Full Text] [Related]
23. Treatment of a malignant pheochromocytoma in a dog using 131I metaiodobenzylguanidine.
Bommarito DA; Lattimer JC; Selting KA; Henry CJ; Cohen M; Johnson GC
J Am Anim Hosp Assoc; 2011; 47(6):e188-94. PubMed ID: 22058369
[TBL] [Abstract][Full Text] [Related]
24. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
25. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
[TBL] [Abstract][Full Text] [Related]
26. Calculating radiation absorbed dose for pheochromocytoma tumors in 131-I MIBG therapy.
Koral KF; Wang XH; Sisson JC; Botti J; Meyer L; Mallette S; Glazer GM; Adler RS
Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):211-8. PubMed ID: 2787315
[TBL] [Abstract][Full Text] [Related]
27. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit.
Tristam M; Alaamer AS; Fleming JS; Lewington VJ; Zivanovic MA
J Nucl Med; 1996 Jun; 37(6):1058-63. PubMed ID: 8683301
[TBL] [Abstract][Full Text] [Related]
28. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
[TBL] [Abstract][Full Text] [Related]
29. Improved detection of disseminated pheochromocytoma using post therapy I-131 MIBG scanning.
Campbell L; Mouratidis B; Sullivan P
Clin Nucl Med; 1996 Dec; 21(12):960-3. PubMed ID: 8957612
[TBL] [Abstract][Full Text] [Related]
30. [131I-MIBG therapy in the treatment of pheochromocytoma in children--own experiences].
Hasse-Lazar K; Krajewska J; Paliczka-Cieślik E; Jurecka-Lubieniecka B; Michalik B; Handkiewicz-Junak D; Roskosz J; Jarzab B
Endokrynol Pol; 2008; 59(3):235-40. PubMed ID: 18615399
[TBL] [Abstract][Full Text] [Related]
31. Adrenal pheochromocytoma.
Novick AC
Urology; 1995 Sep; 46(3):405. PubMed ID: 7660520
[No Abstract] [Full Text] [Related]
32. Clinical review: Current treatment of malignant pheochromocytoma.
Scholz T; Eisenhofer G; Pacak K; Dralle H; Lehnert H
J Clin Endocrinol Metab; 2007 Apr; 92(4):1217-25. PubMed ID: 17284633
[TBL] [Abstract][Full Text] [Related]
33. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.
Fishbein L; Bonner L; Torigian DA; Nathanson KL; Cohen DL; Pryma D; Cengel KA
Horm Metab Res; 2012 May; 44(5):405-10. PubMed ID: 22566196
[TBL] [Abstract][Full Text] [Related]
34. Radionuclide therapy of neural crest tumors.
Voûte PA; Hoefnagel CA; de Kraker J; Evans AE; Hayes A; Green A
Med Pediatr Oncol; 1987; 15(4):192-5. PubMed ID: 3657706
[TBL] [Abstract][Full Text] [Related]
35. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma.
Wakabayashi H; Taki J; Inaki A; Nakamura A; Kayano D; Fukuoka M; Matsuo S; Nakajima K; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):839-46. PubMed ID: 23864328
[TBL] [Abstract][Full Text] [Related]
36. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands.
Hartley A; Spooner D; Brunt AM
Clin Oncol (R Coll Radiol); 2001; 13(5):361-6. PubMed ID: 11716230
[TBL] [Abstract][Full Text] [Related]
37. [Clinical remission and reduction of malignant pheochromocytoma treated with iodine-131-meta-iodobenzylguanidine].
Piñero A; Hernández A; Rodríguez JM; Parrilla P
Med Clin (Barc); 1996 Nov; 107(19):755-6. PubMed ID: 9082096
[No Abstract] [Full Text] [Related]
38. Brain uptake of iodine-131 metaiodobenzylguanidine following therapy of malignant pheochromocytoma.
Dwamena BA; Zempel S; Klopper JF; Van Heerden B; Wieland D; Shapiro B
Clin Nucl Med; 1998 Jul; 23(7):441-5. PubMed ID: 9676949
[TBL] [Abstract][Full Text] [Related]
39. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma.
Safford SD; Coleman RE; Gockerman JP; Moore J; Feldman JM; Leight GS; Tyler DS; Olson JA
Surgery; 2003 Dec; 134(6):956-62; discussion 962-3. PubMed ID: 14668728
[TBL] [Abstract][Full Text] [Related]
40. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.
van Hulsteijn LT; Niemeijer ND; Dekkers OM; Corssmit EP
Clin Endocrinol (Oxf); 2014 Apr; 80(4):487-501. PubMed ID: 24118038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
